Anesthetic Implications of Chronic Medications

  • Tamas A. Szabo
  • R. David Warters


The prevention and recognition of drug-related problems in older adults are of paramount importance. Medicationrelated problems are estimated to cause 106,000 deaths annually at a cost of $75-85 billion. Elderly patients presenting for surgery are often taking a large number and wide variety of chronic medications, greatly complicating their preoperative assessment and anesthesia management. The often daunting task of evaluating the potential interactions of these medications with one another as well as anesthetic medications is further complicated by the large number of inappropriate medications prescribed in this age group.


Negative Inotropic Effect Inappropriate Medication Beta Agonist Chronic Medication Beers Criterion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157(14): 1531–1536.CrossRefGoogle Scholar
  2. 2.
    Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003; 163(22): 2716–2724.PubMedCrossRefGoogle Scholar
  3. 3.
    van der Hooft CS, Jong GW, Dieleman JP, et al. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria—a population-based cohort study. Br J Clin Pharmacol 2005; 60(2): 137–144.PubMedCrossRefGoogle Scholar
  4. 4.
    Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272(4): 292–296.PubMedCrossRefGoogle Scholar
  5. 5.
    Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001; 286(22): 2823–2829.PubMedCrossRefGoogle Scholar
  6. 6.
    Pitkala KH, Strandberg TE, Tilvis RS. Inappropriate drug prescribing in home-dwelling, elderly patients: a populationbased survey. Arch Intern Med 2002; 162(15): 1707–1712.PubMedCrossRefGoogle Scholar
  7. 7.
    Guilleminault C. Benzodiazepines, breathing, and sleep. Am J Med 1990; 88(3A): 25S–28S.PubMedCrossRefGoogle Scholar
  8. 8.
    Faust RJ, Cucchiara RF, Rose SH, et al. Anesthesiology Review. 3rd ed. Philadelphia: Churchill Livingstone; 2002.Google Scholar
  9. 9.
    Sanders LD, Whitehead C, Gildersleve CD, et al. Interaction of H2-receptor antagonists and benzodiazepine sedation. A double-blind placebo-controlled investigation of the effects of cimetidine and ranitidine on recovery after intravenous midazolam. Anaesthesia 1993; 48(4): 286–292.PubMedCrossRefGoogle Scholar
  10. 10.
    Salonen M, Reid K, Maze M. Synergistic interaction between alpha 2-adrenergic agonists and benzodiazepines in rats. Anesthesiology 1992; 76(6): 1004–1011.PubMedCrossRefGoogle Scholar
  11. 11.
    Ruff R, Reves JG. Hemodynamic effects of a lorazepamfentanyl anesthetic induction for coronary artery bypass surgery. J Cardiothorac Anesth 1990; 4(3): 314–317.PubMedCrossRefGoogle Scholar
  12. 12.
    Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992; 14(2): 292–305.PubMedGoogle Scholar
  13. 13.
    Luger TJ, Hill HF, Schlager A. Can midazolam diminish sufentanil analgesia in patients with major trauma? A retrospective study of 43 patients. Drug Metabol Drug Interact 1992; 10: 177–184.PubMedGoogle Scholar
  14. 14.
    Megarbane B, Leprince P, Deye N, et al. Extracorporeal life support in a case of acute carbamazepine poisoning with life-threatening refractory myocardial failure. Intensive Care Med 2006; 32(9): 1409–1413.PubMedCrossRefGoogle Scholar
  15. 15.
    Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31(3): 198–214.Google Scholar
  16. 16.
    Sweet RA, Brown EJ, Heimberg RG, et al. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry 1995; 56(5): 196–201.PubMedGoogle Scholar
  17. 17.
    Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. J Clin Pharmacol 1989; 29(6): 529–532.PubMedGoogle Scholar
  18. 18.
    Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95(4): 434–441.PubMedCrossRefGoogle Scholar
  19. 19.
    Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 2004; 10(20): 2463–2475.PubMedCrossRefGoogle Scholar
  20. 20.
    Tung A, Chang JL, Garvey E, et al. Tricyclic antidepressants and cardiac arrhythmias during halothane-pancuronium anesthesia. Anesth Prog 1981; 28(2): 44, 48–49.PubMedGoogle Scholar
  21. 21.
    Young R. Update on Parkinson’s disease. Am Fam Physician 1999; 59(8): 2155–2167.PubMedGoogle Scholar
  22. 22.
    Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol 2004; 58: 1–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer’s type. Clin Pharmacokinet 2002; 41: 225–234.PubMedCrossRefGoogle Scholar
  24. 24.
    Watkins PB, Zimmermann HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271: 992–998.PubMedCrossRefGoogle Scholar
  25. 25.
    Burns A, O’Brien J, BAP Dementia Consensus Group, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732–755.PubMedCrossRefGoogle Scholar
  26. 26.
    Stoelting RK. Pharmacology and Physiology in Anesthetic Practice. 3rd ed. Philadelphia: Lippincott-Raven; 1999.Google Scholar
  27. 27.
    Van Deusen SK, Birkhahn RH, Gaeta TJ. Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. J Toxicol Clin Toxicol 2003; 41(4): 373–376.PubMedCrossRefGoogle Scholar
  28. 28.
    Dec GW. Digoxin remains useful in the management of chronic heart failure. Med Clin North Am 2003; 87(2): 317–337.PubMedCrossRefGoogle Scholar
  29. 29.
    Bartolone RS, Rao TL. Dysrhythmias following muscle relaxant administration in patients receiving digitalis. Anesthesiology 1983; 58(6): 567–569.PubMedCrossRefGoogle Scholar
  30. 30.
    Crome P, Curl B, Holt D, et al. Digoxin and cimetidine: investigation of the potential for a drug interaction. Hum Toxicol 1985; 4(4): 391–399.PubMedGoogle Scholar
  31. 31.
    Mouser B, Nykamp D, Murphy JE, et al. Effect of cimetidine on oral digoxin absorption. DICP 1990; 24(3): 286–288.PubMedGoogle Scholar
  32. 32.
    Rooney RT, Marijic J, Stommel KA, et al. Additive cardiac depression by volatile anesthetics in isolated hearts after chronic amiodarone treatment. Anesth Analg 1995; 85(5): 917–924.CrossRefGoogle Scholar
  33. 33.
    Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med 2004; 25(1): 65–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Ursella S, Testa A, Mazzone M, et al. Amiodarone-induced thyroid dysfunction in clinical practice. Eur Rev Med Pharmacol Sci 2006; 10(5): 269–278.PubMedGoogle Scholar
  35. 35.
    Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999; 1(4): 206–207.PubMedGoogle Scholar
  36. 36.
    Feringa HH, Bax JJ, Boersma E, et al. High-dose betablockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation 2006; 114(1 Suppl): I344–349.PubMedGoogle Scholar
  37. 37.
    Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 2006; 98(8): 1115–1119.PubMedCrossRefGoogle Scholar
  38. 38.
    Pedersen ME, Cockcroft JR. The latest generation of betablockers: new pharmacologic properties. Curr Hypertens Rep 2006; 8(4): 279–286.PubMedCrossRefGoogle Scholar
  39. 39.
    Hayashi Y, Sumikawa K, Kuro M, et al. Roles of beta 1-and beta 2-adrenoceptors in the mechanism of halothane myocardial sensitization in dogs. Anesth Analg 1991; 72(4): 435–439.PubMedCrossRefGoogle Scholar
  40. 40.
    Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47(1): 34–57.PubMedCrossRefGoogle Scholar
  41. 41.
    Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. BMJ 1987; 294: 155–156.PubMedGoogle Scholar
  42. 42.
    Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991; 21(4): 285–307.PubMedCrossRefGoogle Scholar
  43. 43.
    Wali FA. Interaction of verapamil with gallamine and pancuronium and reversal of combined neuromuscular blockade with neostigmine and edrophonium. Eur J Anaesthesiol 1986; 3(5): 385–393.PubMedGoogle Scholar
  44. 44.
    Baciewicz AM, Baciewicz FA Jr. Effect of cimetidine and ranitidine on cardiovascular drugs. Am Heart J 1989; 118(1): 144–154.PubMedCrossRefGoogle Scholar
  45. 45.
    Ray S, Dargie H. Infarct-related heart failure: the choice of ACE inhibitor does not matter. Cardiovasc Drugs Ther 1994; 8(3): 433–436.PubMedCrossRefGoogle Scholar
  46. 46.
    Cruz CS, Cruz A, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003; 18(9): 1814–1819.PubMedCrossRefGoogle Scholar
  47. 47.
    Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16(3): 360–366.PubMedCrossRefGoogle Scholar
  48. 48.
    Wu RS, Wu KC, Wong TK, et al. Effects of fenoterol and ipratropium on respiratory resistance of asthmatics after tracheal intubation. Br J Anaesth 2000; 84(3): 358–362.PubMedGoogle Scholar
  49. 49.
    Koehntop DE, Liao JC, Van Bergen FH. Effects of pharmacologic alterations of adrenergic mechanisms by cocaine, tropolone, aminophylline, and ketamine on epinephrineinduced arrhythmias during halothane-nitrous oxide anesthesia. Anesthesiology 1977; 46(2): 83–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Hirshman CA, Krieger W, Littlejohn G, et al. Ketamineaminophylline-induced decrease in seizure threshold. Anesthesiology 1982; 56(6): 464–467.PubMedCrossRefGoogle Scholar
  51. 51.
    Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39(4): 295–309.PubMedCrossRefGoogle Scholar
  52. 52.
    Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth 1990; 65(2): 220–224.PubMedCrossRefGoogle Scholar
  53. 53.
    Gaga BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118(6): 612–617.CrossRefGoogle Scholar
  54. 54.
    Cappuzzo KA. Anticoagulation in elderly patients who fall frequently: a therapeutic dilemma. Consult Pharm 2005; 20(7): 601–605.PubMedGoogle Scholar
  55. 55.
    Sloane PD, Zimmerman S, Brown LC, et al. Inappropriate medication prescribing in residential care/assisted living facilities. J Am Geriatr Soc 2002; 50(6): 1001–1011.PubMedCrossRefGoogle Scholar
  56. 56.
    Kubler PA, Pillans PI, Marrinan MC, et al. Concordance between clopidogrel use and prescribing guidelines. Intern Med J 2004; 34(12): 663–667.PubMedCrossRefGoogle Scholar
  57. 57.
    Maio V, Yuen EJ, Novielli K, et al. Potentially inappropriate medication prescribing for elderly outpatients in Emilia Romagna, Italy: a population-based cohort study. Drugs Aging 2006; 23(11): 915–924.PubMedCrossRefGoogle Scholar
  58. 58.
    Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 1987; 294(6565): 147–150.Google Scholar
  59. 59.
    Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly. Drugs Aging 1991; 1(2): 130–143.PubMedCrossRefGoogle Scholar
  60. 60.
    Butt JH, Barthel JS, Moore RA. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal antiinflammatory drugs. Natural history, symptomatology, and significance. Am J Med 1988; 84(2A): 5–14.PubMedCrossRefGoogle Scholar
  61. 61.
    Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25(8): 1013–1015.PubMedCrossRefGoogle Scholar
  62. 62.
    Caterino JM, Emond JA, Camargo CA Jr. Inappropriate medication administration to the acutely ill elderly: a nationwide emergency department study, 1992–2000. J Am Geriatr Soc 2004; 52(11): 1847–1855.PubMedCrossRefGoogle Scholar
  63. 63.
    Fong HK, Sands LP, Leung JM. The role of postoperative analgesia in delirium and cognitive decline in elderly patients: a systematic review. Anesth Analg 2006; 102: 1255–1266.PubMedCrossRefGoogle Scholar
  64. 64.
    Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20(1): 23–57.PubMedCrossRefGoogle Scholar
  65. 65.
    Barkin RL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther 2006; 13(6): 534–542.PubMedCrossRefGoogle Scholar
  66. 66.
    Kamal-Bahl SJ, Stuart BC, Beers MH. Propoxyphene use and risk for hip fractures in older adults. Am J Geriatr Pharmacother 2006; 4(3): 219–226.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Tamas A. Szabo
    • 1
  • R. David Warters
    • 1
  1. 1.Department of Anesthesiology Ralph H. Johnson Veterans AdministrationMedical CenterCharlestonUSA

Personalised recommendations